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Abstract
Background: The incidence of invasive cervical cancer in HIV-positive women is higher than in the general population. 
There is evidence that HIV-positive women do not participate sufficiently in cervical cancer screening in Italy, where 
cervical cancer is more than 10-fold higher in women with AIDS than in the general population. The aim of the present 
study was to evaluate the history of Pap-smear in HIV-positive women in Italy in recent years. We also examined the 
sociodemographic, clinical, and organizational factors associated with adherence to cervical cancer screening.
Methods: A cross-sectional study was conducted between July 2006 and June 2007 in Emilia-Romagna region 
(Northern Italy). All HIV-positive women who received a follow-up visit in one of the 10 regional infectivology units 
were invited to participate. History of Pap-smear, including abnormal smears and subsequent treatment, was 
investigated through a self-administered anonymous questionnaire. The association between lack of Pap-smear in the 
year preceding the interview and selected characteristics was assessed by means of odds ratios (OR) and 95% 
confidence intervals adjusted for study centre and age.
Results: A total of 1,002 HIV-positive women were interviewed. Nine percent reported no history of Pap-smear, and 
39% had no Pap-smear in the year prior to the date of questionnaire (last year). The lack of Pap-smear in the last year 
was significantly associated with age <35 years (OR = 1.4, compared to age ≥45 years), lower education level (OR = 1.3), 
first HIV-positive test in the last 2 years (OR = 1.4), and CD4 count <200 cells/μl (OR = 1.6). Conversely, when women 
were advised by a gynecologist rather than other health workers to undergo screening, it significantly increased 
adherence. Non-significantly higher proportions of lack of Pap-smear in the last year were found in women born in 
Central-Eastern Europe (OR = 1.8) and Africa (OR = 1.3). No difference in history of Pap-smear emerged by mode of HIV-
acquisition or AIDS status.
Three hundred five (34%) women reported a previous abnormal Pap-smear, and of the 178 (58%) referred for 
treatment, 97% complied.
Conclusions: In recent years the self-reported history of Pap-smear in HIV-positive women, in some public clinics in 
Italy, is higher than previously reported, but further efforts are required to make sure cervical cancer screening is 
accessible to all HIV-positive women.
Background
The incidence of invasive cervical cancer in HIV-positive
women is higher than in the general population [1]. This
elevated incidence varies from country to country
depending on study site and characteristics of the popula-
tions under study [2-4]. The weaker association between
HIV-infection and cervical cancer risk in some countries
seems to be explained by competing risks of death (e.g.: in
Africa), or early detection of pre-invasive lesions (e.g.: in
the United States) [5].
Effective screening and early treatment of precancerous
cervical lesions are key factors in preventing the progres-
sion to invasive cervical cancer in both HIV-positive and
-negative women [6]. Recent guidelines recommend that,
following two initial normal Pap-smears at a 6-month
interval, all HIV-positive women should undergo annual
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cervical cytologic examination [7]. In addition, it is rec-
ommended that all immunosuppressed women with
atypical squamous cells undergo colposcopy [7].
In the United States, approximately 80% of HIV-posi-
tive women reported a history of Pap-smear in the past
year [8,9]. Low incidence rates of invasive cervical cancer,
similar to those among HIV-negative women, were found
among adequately screened HIV-positive women [10]. In
contrast, there is evidence that HIV-positive women do
not participate sufficiently in cervical cancer screening in
Southern European countries such as Italy and Spain,
where cervical cancer incidence is more than 10-fold
higher in women with AIDS than in general population
[3,5,11,12].
In Italy, one-half of women with invasive cervical can-
cer as the AIDS-defining illness (3% of all women with
AIDS) had their first HIV-positive test ≥10 years before
cancer diagnosis [12]. This long interval suggests a failure
to stop the progression of precancerous lesions through
screening, despite the knowledge of HIV infection.
A large cross-sectional study showed not only a scanty
use of Pap-smear among HIV-positive Italian women, but
also that these women did not know that a Pap-test was
used to prevent cervical cancer [13]. In addition, a survey
conducted among clinicians in 27 Italian HIV centers
showed low compliance with the published guidelines on
gynecologic follow-up of HIV-positive women in Italy
[14].
The aim of the present study was to evaluate the recent
history of Pap-smear in HIV-positive women in Italy fol-
lowed in public HIV clinics. We also examined the socio-
demographic, clinical, and organizational factors
associated with the lack of adherence to screening recom-
mendations.
Methods
Study population
A cross-sectional study was conducted between July 2006
and June 2007 the in Emilia-Romagna Region (Northern
Italy). At end of 2006, this region covered an area of more
than 22.000 km2 (7% of Italy), with a population of 4.2
million inhabitants (7% of Italian population). Approxi-
mately 1,500 HIV-positive women are estimated to live in
the Emilia-Romagna Region [15,16]. All HIV-positive
women who underwent a follow-up visit (recommended
every 6-months) in one of the 10 regional infectivology
units were invited to participate. The study period was
limited to one year in order to reduce the possibility of
duplication.
A total of 1,108 HIV-positive women were invited and
1,002 (90.4%) accepted to participate. Study aims were
explained and written informed consent was obtained
from study women, who subsequently completed a self-
administered anonymous questionnaire. History of Pap-
smear was investigated in detail to assess lifetime screen-
ing, including dates of first and last Pap-smear, and num-
ber of Pap-smears in the three years preceding the
questionnaire. The questionnaire included additional
items on the place where Pap-smear was taken, HPV test-
ing, history of abnormal smears, and treatment of cervi-
cal lesions. Other collected data included
sociodemographic factors (e.g., age, education level, and
country of birth), smoking and reproductive history, sex-
ual habits (e.g., age at first intercourse, lifetime number of
sexual partners, and use of contraceptive methods), and
history of HIV infection (e.g., date of first HIV-positive
test and most probable route of HIV acquisition). In a
separate form, the attending infectivologist reported
information on the course of HIV-infection (e.g.: HIV-
related hospitalization, last CD4 count and HIV RNA val-
ues, AIDS status, and AIDS-defining conditions).
The Ethical Committees of all participating centers
approved the study protocol.
Statistical analysis
Odds ratios (ORs) and 95% confidence intervals (CIs)
were used as the measures of association between history
of Pap-smear and women's characteristics, and were esti-
mated using logistic regression models adjusted for study
centre and age [17,18]. Estimates were also calculated
including further adjustment for area of birth, mode of
HIV acquisition, and time since first HIV-positive test.
Results
A total of 1,002 HIV-positive women completed the
questionnaire. The median age was 41 years and the vast
majority of women (87%) fell in the 30-to-49-year age
range. Eighty percent of our study women were born in
Italy and nearly two-thirds reported sexual intercourse as
the route of HIV acquisition. One hundred eighty (18%)
women had a previous AIDS diagnosis and 56% had their
first HIV-positive test 10 or more years prior to the ques-
tionnaire.
Nine percent of women reported no history of Pap-
smear and 305 (34%) had abnormal Pap-smear results
(Figure 1). Women with no history of Pap-smear were
younger and more likely to be born in Central-Eastern
Europe (15%) or Africa (29%) than women reporting pre-
vious Pap-smears (3% and 9%, respectively) (data not
shown). HPV test was reported by only 27% of women
(Figure 1).
Overall, 607 (61%) of the 1,002 HIV-positive women
had a Pap-smear in the year prior to questionnaire (last
year, Table 1). Women younger than 35 years (OR, com-
pared to age ≥45 = 1.4; 95%CI: 1.0-2.0), those with lower
education level (OR = 1.3; 95%CI: 1.0-1.7), those with
recent first HIV-positive test (OR for ≤2 years vs ≥10
years = 1.4; 95%CI: 1.0-2.1), or a CD4 count of <200 cells/Dal Maso et al. BMC Cancer 2010, 10:310
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μl (OR compared to ≥500 = 1.6; 95%CI: 1.0-2.5) were
more likely to have no history of Pap-smear in the year
before questionnaire. Non-significantly higher propor-
tions of lack of Pap-smear in the last year were found in
women born in Central-Eastern Europe (OR = 1.8;
95%CI: 0.9-3.6) and Africa (OR = 1.3; 95%CI: 0.8-2.0). No
difference in Pap-smear history emerged by mode of HIV
acquisition, or AIDS status.
Receiving screening advice from a gynecologist rather
than an infectivologist (OR = 0.6; 95%CI: 0.4-0.9) and his-
tory of abnormal Pap-smear (OR = 0.5; 95%CI: 0.3-0.6)
were associated with better screening participation
(Table 1). The multivariate models, including additional
terms for area of birth, mode of HIV acquisition, and time
since first HIV-positive test, did not materially modify
the risk estimates even if associations with age and first
HIV-positive test were not statistically significant (Table
1).
Among the 305 women who reported a previous abnor-
mal Pap-smear, treatment was recommended for 178
(58%); of whom, 173 (97%) complied. Among the 127
(42%) women who were referred for further testing but
not treatment, 84 (66%) underwent all the recommended
follow-up tests.
Among the 178 women to whom treatment was recom-
mended, 145 (81%) reported colposcopy and all follow-up
tests. Conization was the surgical procedure most fre-
quently reported by patients (122, 69%), followed by hys-
terectomy (19, 11%), and cryotherapy (8, 4%).
Discussion
This study was the first attempt to provide estimates of
self-reported Pap-smear history in HIV-positive women
attending infectivology units of a large Italian region. We
found that 91% of women had had at least one Pap-smear
in their lifetime, and 61% reported a Pap-smear in the last
year. These proportions are similar to the ones reported
by the general population of the same age and geographi-
cal area (95% and 47%, respectively) (Carrozzi and Ber-
tozzi, personal communication), and substantially higher
than those reported (43%) in 2001 by a physician-based
Italian survey [14]. Increase in the number of Pap-smears
performed, however, is difficult to evaluate, given the dif-
ferent study designs of previous studies conducted in
Italy [13,14]. The proportion of women who had a Pap-
smear in the last year, however, remains suboptimal with
respect to current guidelines regarding HIV-positive
women (annual Pap-smear recommended to all patients),
and is lower than the estimates (approximately 80%)
reported in the USA [8,9].
Factors associated with lack of recent Pap-smear were
young age (<35 years), recent HIV diagnosis (≤2 years),
and more advanced diseases (CD4 count at last visit <200
cells/μL). Conversely, receiving screening advice from a
gynecologist significantly improved the adherence to
Pap-smear. We found less influence of education level or
country of birth than a previous cross-sectional study
conducted in Rome [13]. As expected, study women
reported a high proportion of previous abnormal Pap-
smears (34%), in agreement with previous reports among
HIV-positive women in Italy [13] and the United States
[8,9].
Overall, our study highlights the difficulties in follow-
ing the recommended protocol of combining routine fol-
low-up of HIV infection with gynecological examination,
which is generally not performed in infectivology units
[5,10]. In addition, patient compliance needs to be
improved [14] and health professionals (e.g., infectious
disease specialists and gynecologists) should thoroughly
inform HIV-positive women (particularly the disadvan-
taged ones) of the importance of Pap-smear to their
health.
The present study has strengths and weaknesses.
Strengths included the high participation among unse-
lected women attending infectivology units. Approxi-
mately 1,500 HIV-positive women are estimated to live in
the Emilia-Romagna Region [15,16] and all women
attending HIV follow-up (recommended every 6 months)
were contacted in a 1-year period. A previous study in
Northern Italy [19] showed that patients infected with
Figure 1 Pap-smear practice and treatment after a positive Pap-
smear in HIV-positive women. Emilia-Romagna Region, Italy, 2006-
2007
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Table 1: Odds ratio (OR) and corresponding 95% confidence intervals (CI) for lack of Pap-smear in the last year by selected 
characteristics
Pap-smear in the last year
Yes No OR† (95%CI) OR‡ (95%CI)
n( % ) n( % )
Total 607 (60.6) 395 (39.4)
Age at interview (years)
≥45 145 (58.7) 102 (41.3) 1 1
40-44 227 (65.6) 119 (34.4) 0.8 (0.5-1.1) 0.8 (0.5-1.1)
35-39 131 (63.3) 76 (36.7) 0.8 (0.6-1.2) 0.8 (0.6-1.2)
<35 104 (51.5) 98 (48.5) 1.4 (1.0-2.0) 1.2 (0.8-1.8)
Education level
High school/University 255 (63.1) 149 (36.9) 1 1
Middle school/Primary 241 (55.9) 190 (44.1) 1.3 (1.0-1.7) 1.3 (1.0-1.7)
Area of birth
Italy 495 (62.1) 302 (37.9) 1 1
Abroad 112 (54.6) 93 (45.4) 1.2 (0.8-1.7) 1.1 (0.8-1.6)
Central-Eastern Europe§ 17 (42.5) 23 (57.5) 1.8 (0.9-3.6) 1.7 (0.8-3.3)
Africa 56 (53.3) 49 (46.7) 1.3 (0.8-2.0) 1.1 (0.7-1.9)
Other countries 39 (65.0) 21 (35.0) 0.8 (0.5-1.5) 0.9 (0.5-1.5)
Mode of HIV acquisition
Sexual 336 (62.1) 205 (37.9) 1 1
Injecting drug use 164 (61.0) 105 (39.0) 1.2 (0.9-1.6) 1.1 (0.8-1.6)
Other/Unknown 107 (55.7) 85 (44.3) 1.2 (0.8-1.6) 1.1 (0.7-1.5)
Time since first HIV+ test (years)
≥10 357 (63.2) 208 (36.8) 1 1
3-9 169 (62.1) 103 (37.9) 0.9 (0.7-1.3) 0.9 (0.7-1.3)
≤2 78 (48.4) 83 (51.6) 1.4 (1.0-2.1) 1.3 (0.9-2.0)
Previous AIDS diagnosis
No 504 (61.3) 318 (38.7) 1 1
Yes 103 (57.2) 77 (42.8) 1.2 (0.9-1.7) 1.2 (0.9-1.7)
CD4 count at last visit (cells/μl)
≥500 284 (63.5) 163 (36.5) 1 1
200-499 271 (58.8) 190 (41.2) 1.2 (0.9-1.6) 1.2 (0.9-1.5)
<200 45 (51.7) 42 (48.3) 1.6 (1.0-2.5) 1.6 (1.0-2.6)
Screening advice received from
Infectivologist 244 (66.8) 121 (33.2) 1 1
Gynecologist 122 (77.2) 36 (22.8) 0.6 (0.4-0.9) 0.6 (0.4-1.0)
Screening program 61 (59.8) 41 (40.2) 1.4 (0.9-2.2) 1.3 (0.8-2.1)
Do not remember 180 (47.7) 197 (52.3) 2.1 (1.5-2.8) 2.2 (1.6-2.9)
Hospitalized for HIV
No 382 (61.8) 236 (38.2) 1 1Dal Maso et al. BMC Cancer 2010, 10:310
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Yes 225 (58.6) 159 (41.4) 1.2 (0.9-1.5) 1.2 (0.9-1.5)
Abnormal Pap-smear#
Never 366 (61.7) 227 (38.3) 1 1
Ever 235 (77.0) 70 (23.0) 0.5 (0.3-0.6) 0.4 (0.3-0.6)
Emilia-Romagna region, Italy, 2006-2007*
* Figures may not add up to totals because of missing values. †Estimates from the logistic regression models adjusted for age and study centre; 
‡Adjusted as † plus terms for area of birth, mode of HIV acquisition, and time since first HIV-positive test. §Included Albania, Bulgaria, Former-
Yugoslavia, Poland, Romania, Hungary, Former-USSR, Czech Republic and Slovakia, Cyprus; #Women reporting no previous Pap-smear were 
excluded
Table 1: Odds ratio (OR) and corresponding 95% confidence intervals (CI) for lack of Pap-smear in the last year by selected 
characteristics (Continued)
HIV through injecting drug use, patients without AIDS
diagnosis, or patients with higher CD4 counts are more
likely to miss medical appointments and discontinue
their follow-up. It is unlikely that HIV-positive women in
the region received their follow-up visits elsewhere, given
the high standard of medical care provided (free of
charge) in Emilia-Romagna in comparison with other
Italian areas. However, the possibility of some socio-
demographic bias in women who did not attend regularly
follow-up cannot be totally ruled out.
The number of self-reported Pap-smears among HIV-
positive women in our study may be an overestimate as
women tend to over-report their participation in cervical
cancer screening in a given timeframe [20]. Confidential-
ity prevented us from linking women's reports with gyne-
cological and cytological records, thus leaving substantial
uncertainty about the actual additional tests and treat-
ments performed. To validate self-reported Pap-smear
use and to follow-up the treatment of HIV-positive
women diagnosed with gynaecological lesions, a new
study is being planned, which will adopt broader confi-
dentiality rules and obtain a written consent to follow-up.
The most important limitation of our survey, however, is
the restriction to HIV-positive women followed by public
clinics in one of the best organized regions of Italy, in
terms of participation and quality of cervical cancer
screening [21,22].
Conclusions
Our study showed that progresses have been made to
screen adequately HIV-positive women in Italy and that
such efforts can also reach the most vulnerable popula-
tions (e.g.: immigrants). The opportunity to prevent cer-
vical cancer in women living with HIV infection should
not be missed; successful implementation of such screen-
ing programs will also teach valuable lessons that could
then be applied to all women [5]. There is, however, still
some scope for improvement, especially in the complete-
ness of treatment and follow-up of HIV-positive women
with an abnormal Pap-smear. Most importantly, much
remains to be done to make sure that the experience of
the Emilia-Romagna Region can be extended to other
parts of Italy.
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